Amgen, Biogen and Takeda talk about R&D on tough targets

What do Amgen, Biogen, and Takeda have in common?

Leaders of research and development at the three biopharma companies shared a stage Thursday at the STAT 2024 Summit in Boston and offered their insights on their differing challenges in a hot space for obesity drugs, an industry that doesn’t favor midsize companies, and a disappointing market for Alzheimer’s treatments — so far.

Their common strategy, in Amgen Chief Scientific Officer Jay Bradner’s words, is to “make medicines for some of the toughest targets for the toughest diseases.”

STAT+ Exclusive Story

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Curative Expands Health Plan to Georgia: $0 Copay, $0 Deductible

What You Should Know: – Curative Insurance Company, a healthcare services innovator, is pleased to announce the expansion of its revolutionary health plan to Georgia.

August 30, 2024

With a $372M megaround, Formation Bio looks to in-license 10+ drugs

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

June 27, 2024

Viking’s GLP-1/GIP receptor agonist helped patients lose almost 15% of their body weight over 13 weeks

Viking Therapeutics’ dual GLP-1/GIP receptor agonist for obesity showed off positive topline data from a Phase II study, with analysts describing the drug as a

February 28, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.